Daisy Genomics, New Day Diagnostics Partner on Colorectal Cancer Detection Platform
The collaboration will combine New Day's liquid biopsy technology with Daisy Genomics' physics-based sequencing platform to advance early CRC screening.
The collaboration will combine New Day's liquid biopsy technology with Daisy Genomics' physics-based sequencing platform to advance early CRC screening.
Sysmex America will distribute Sentinel Diagnostics SENTiFIT 270 and 800 analyzers in Canada for colorectal cancer (CRC) screening.
The FDA approved Exact Sciences' Cologuard Plus test, a stool DNA test that enhances colorectal cancer and precancerous lesion detection.
A new study reveals that an at-home colorectal cancer screening test, FIT, can reduce the risk of colorectal cancer death by 33%.
Read MoreMainz Biomed has applied for FDA Breakthrough Device Designation for its advanced non-invasive colorectal cancer screening test.
Read MoreThe new collaboration aims to enhance colorectal cancer (CRC) screening using advanced diagnostic platforms and novel biomarkers.
Read MoreMainz Biomed unveiled findings of the eAArly DETECT study that demonstrated high sensitivity and specificity of their colorectal cancer test.
Read MoreThe FDA’s Medical Devices Advisory Committee recommended approval of Guardant Health’s Shield blood test for colorectal cancer screening.
Read MoreA new study found that 7.4% of patients repeated fecal testing rather than proceeding directly to colonoscopy as guidelines recommend.
Read MoreOffering a choice between colonoscopy and a take-home screening kit more than doubled colorectal cancer screening rates.
Read MoreMainz Biomed N.V. announced results from a clinical study to evaluating integrating its portfolio into its colorectal cancer screening tool.
Read MoreMainz Biomed will present the findings of a study that evaluated its multimodal screening test for the detection of colorectal cancer.
Read MoreGeneoscopy received U.S. FDA approval for ColoSense, a noninvasive colorectal cancer screening test that uses RNA biomarkers.
Read MoreA significant gap exists in ensuring timely follow-up with colonoscopy after a positive stool test, hindering the effectiveness of screening.
Read MoreNew studies are cautioning against the use of blood tests to replace established colorectal cancer screening tests.
Read MoreResearchers say the test has the best performance for the detection of both colorectal cancer and advanced precancerous polyps.
Read MoreThe blood test is intended for screening colorectal cancer in people who are of average risk and not experiencing symptoms.
Read MoreThe PreveCol test for cancer is aimed at the early detection of biomarkers in blood associated with colorectal neoplasia.
Read More